These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10651108)

  • 1. Nocturnal sleep structure and temperature slope in MPTP treated monkeys.
    Almirall H; Pigarev I; de la Calzada MD; Pigareva M; Herrero MT; Sagales T
    J Neural Transm (Vienna); 1999; 106(11-12):1125-34. PubMed ID: 10651108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M; Fukuda T
    Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
    Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclinical damage to the nigrostriatal dopamine system by MPTP as a model of preclinical Parkinson's disease: a review.
    Burns RS
    Acta Neurol Scand Suppl; 1991; 136():29-36. PubMed ID: 1801534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
    Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
    Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
    [No Abstract]   [Full Text] [Related]  

  • 7. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
    Goldberg JA; Boraud T; Maraton S; Haber SN; Vaadia E; Bergman H
    J Neurosci; 2002 Jun; 22(11):4639-53. PubMed ID: 12040070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
    Calon F; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Exp Neurol; 2000 May; 163(1):191-9. PubMed ID: 10785458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys.
    Barcia C; Bautista V; Sánchez-Bahillo A; Fernández-Villalba E; Navarro-Ruis JM; Barreiro AF; Poza Y Poza M; Herrero MT
    Neuroendocrinology; 2003 Aug; 78(2):118-28. PubMed ID: 12915764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of [corrected] nigrostriatal dopamine system in learning to perform sequential motor tasks in a predictive manner.
    Matsumoto N; Hanakawa T; Maki S; Graybiel AM; Kimura M
    J Neurophysiol; 1999 Aug; 82(2):978-98. PubMed ID: 10444692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
    Hyacinthe C; Barraud Q; Tison F; Bezard E; Ghorayeb I
    Neurobiol Dis; 2014 Mar; 63():20-4. PubMed ID: 24211719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel effect of MPTP: the selective suppression of paradoxical sleep in cats.
    Pungor K; Papp M; Kékesi K; Juhász G
    Brain Res; 1990 Aug; 525(2):310-4. PubMed ID: 2253031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of sleep-wakefulness structure in parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and oxotremorine].
    Gugutsidze DA; Nerobkova LN; Boronina TA
    Biull Eksp Biol Med; 1989 Aug; 108(8):206-9. PubMed ID: 2804326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontal cognitive impairments and saccadic deficits in low-dose MPTP-treated monkeys.
    Slovin H; Abeles M; Vaadia E; Haalman I; Prut Y; Bergman H
    J Neurophysiol; 1999 Feb; 81(2):858-74. PubMed ID: 10036286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Operant behavioral disorders in monkeys with an MPTP-induced Parkinson-like syndrome].
    Burov IuV; Shul'govskiĭ VV; Petrov GV; Tereshchenko LV; Iudin AV
    Fiziol Zh Im I M Sechenova; 1995 Oct; 81(10):113-6. PubMed ID: 9026250
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of amphetamine, diazepam and caffeine on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in Cynomolgus monkeys.
    Authier S; Bassett L; Pouliot M; Rachalski A; Troncy E; Paquette D; Mongrain V
    J Pharmacol Toxicol Methods; 2014; 70(1):86-93. PubMed ID: 24878255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
    Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
    Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic aspects of the behavior of MPTP and some analogues.
    Tipton KF; McCrodden JM; Sullivan JP
    Adv Neurol; 1993; 60():186-93. PubMed ID: 8420134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.